DB05060ExperimentalSmall molecule
R1626 is one of a new class of hepatitis C therapies called polymerase inhibitors. It achieves significant reductions in viral load in chronic hepatitis C patients infected with the difficult... R1626 is very effective in inhibiting viral replication.
- Primary indication
- Investigated for use/treatment in hepatitis (viral, C).Curator reviewed
Resolves to
Targets
What you can answer from here — as of April 02, 2025
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with R1626, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account